Eli Lilly's latest Zyprexa settlement will not affect civil or criminal investigations pending over Zyprexa from state attorneys general and federal prosecutors, which are continuing.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
The Baltimore Sun reports (below) that in a paper scheduled for publication in the journal Epidemiology and Infection, a Harvard University-led team proposes that a vitamin D deficiency caused by inadequate winter sun exposure may predispose people to infection.
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…
Forbes: Judgment Day for the FDA, Pfizer Wed, 9 Feb 2005 On Feb. 16-18 COX-2 Inhibitor Safety Issues will be the focus of an FDA Advisory Committee and (simultaneously) the European Medicines Agency (EMA). The entire drug industry will be watching with bated breath. Which causal explanation will be offered…
Cong Hinchey PRESS CONFERENCE Re: Drug Co. Influence on FDA Sat, 10 Jul 2004 New York Congressman Maurice Hinchey (House Appropriations Committee) is holding a press conference on Tuesday, July 13, 2004, at 10:30 AM to address issues of concern about undue influence by drug manufacturers on FDA policy and…
MEMORANDUM Date: June 10, 2002 From: THE ALLIANCE FOR HUMAN RESEARCH PROTECTION Re: Opposition to AB 2328 To: Members of the California Health and Human Services Committee and Staff: Senator Deborah Ortiz (Chair), Mr. John Miller Senator Ray Haynes (Vice Chair), Ms. Debbie Rogers Senator Jim Battin, Ms. Katie Tinney…
